NCT04344795 | Phase 1a/1b study of TPST-1495 alone and with Pembrolizumab in subjects with solid tumors | Solid tumor, microsatellite stable colorectal cancer, adenocarcinoma of the lung, squamous cell carcinoma of head and neck, bladder cancer, triple-negative breast cancer, gastric cancer | TPST-1495 | Pembrolizumab | Recruiting | 1 |
NCT03658772 | Grapiprant and Pembrolizumab in patients with advanced or progressive MSS colorectal cancer | Microsatellite stable colorectal cancer | Grapiprant | Pembrolizumab | Recruiting | 1 |
NCT03696212 | Grapiprant (ARY-007) and Pembrolizumab in patients with advanced or metastatic post-PD-1/L1 NSCLC adenocarcinoma | Non–small-cell lung cancer adenocarcinoma | Grapiprant and | Pembrolizumab | Recruiting | 1, 2 |
NCT02538432 | Phase 2 trial of EP4 receptor antagonist AAT-007 (RQ-07; CJ-023,423) in advanced solid tumors | Prostate cancer non–small-cell lung cancer breast cancer | RQ-00000007 | Gemcitabine | Withdrawn | 2 |
NCT03163966 | A study of the EP4 antagonist CR6086 in combination with methotrexate, in DMARD-naïve patients with early rheumatoid arthritis | Rheumatoid arthritis, DMARD-naïve. and early disease patients | CR6086 | Methotrexate | Unknown | 2 |
NCT00957983 | EP4 receptor antagonism and prostaglandin E2 in a human headache model | Headache, migraine | BGC20-1531 | | Completed | 1, 2 |